Journal of Cancer Research and Clinical Oncology

, Volume 130, Issue 9, pp 537–545 | Cite as

Gene expression patterns as marker for 5-year postoperative prognosis of primary breast cancers

  • Masamitsu Onda
  • Mitsuru Emi
  • Hisaki Nagai
  • Takemitsu Nagahata
  • Kouji Tsumagari
  • Takashi Fujimoto
  • Futoshi Akiyama
  • Goi Sakamoto
  • Masujirou Makita
  • Fujio Kasumi
  • Yoshio Miki
  • Toshihiro Tanaka
  • Tatsuhiko Tsunoda
  • Yusuke Nakamura
Original Paper
First Online:
Received:
Accepted:

Abstract

Purpose

To establish the novel prognostic markers for breast cancer, gene expression profile was examined genome-wide.

Methods

We used cDNA microarray consisting of 18,432 human genes to compare genome-wide expression profiles of eight primary breast cancers, four from patients who died of breast cancer within 5 years after surgery (5D group) and four who survived disease-free for more than 5 years (5S group).

Results

We identified 21 genes whose expression was greater in tumors from the 5D group than in 5S tumors, and 23 with higher expression in the 5S group than in the 5D group. We established a Prognostic Index (PI) for prediction of postoperative prognosis, based on the aberrant expression profiles of ten of those genes. Among 20 additional cases chosen blindly, ten presented with high prognostic scores (>7, good) according to the PI; the remaining ten cases revealed scores <7 (poor). The PI predicted the actual 5-year clinical outcomes of these 20 cases with 100% accuracy.

Conclusion

Our PI system is reliable in clinical settings for predicting postoperative risk for breast cancer. The extensive list of genes provides valuable information about progression of breast cancer and suggests potential target molecules for treating this disease.

Keywords

cDNA microarray Breast cancer Gene expression Postoperative prognosis Genetic marker 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

We thank Shizuyo Miyamoto and Naoko Shimbo for excellent technical assistance, Mihoko Tsuruta, Mayumi Tanaka, and Kyoko Shimizu for secretarial assistance. This work was supported by special grants for Strategic Advanced Research on “Cancer” from the Ministry of Education, Science, Sports and Culture of Japan; and by a Research for the Future Program Grant of The Japan Society for the Promotion of Science

References

  1. Anonymous (1989) The general rules for clinical and pathological recording of breast cancer. Japanese Breast Cancer Society. Jpn J Surg 19:612–32PubMedGoogle Scholar
  2. Carr JA, Havstad S, Zarbo RJ, Divine G, Mackowiak P, Velanovich V (2000) The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg 135:1469–1474CrossRefPubMedGoogle Scholar
  3. Costa SD, Lange S, Klinga K, Merkle E, Kaufmann M (2002) Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer--results of the analysis of 670 patients with 11 years of follow-up. Eur J Cancer 38:1329–1334CrossRefPubMedGoogle Scholar
  4. Couzin J (2002) Genomics. Taking aim at Celera’s shotgun. Science 295:1817CrossRefGoogle Scholar
  5. Dawson PJ, Ferguson DJ, Karrison T (1982) The pathological findings of breast cancer in patients surviving 25 years after radical mastectomy. Cancer 50:2131–2138PubMedGoogle Scholar
  6. Egawa C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S (2002) High BRCA2 mRNA expression predicts poor prognosis in breast cancer patients. Int J Cancer 98:879–882CrossRefPubMedGoogle Scholar
  7. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedGoogle Scholar
  8. Hirano A, Utada Y, Haga S, Kajiwara T, Sakamoto G, Kasumi F, Nakamura Y, Emi M (2001) Allelic losses as prognostic markers for breast cancers. Int J Clin Oncol 6:6–12PubMedGoogle Scholar
  9. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, West M, Nevins JR, Huang AT (2003) Gene expression predictors of breast cancer outcomes. Lancet 361:1590–1596CrossRefPubMedGoogle Scholar
  10. Hupperets PS, Volovics L, Schouten LJ, Jager JJ, Schouten HC, Hillen HF, Blijham GH (1997) The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer. Am J Clin Oncol 20:546–551CrossRefPubMedGoogle Scholar
  11. Manos EJ, Jones DA (2001) Assessment of tumor necrosis factor receptor and Fas signaling pathways by transcriptional profiling. Cancer Res 61:433–438PubMedGoogle Scholar
  12. McPherson JD, Marra M, Hillier L, Waterston RH, Chinwalla A, Wallis J, Sekhon M, Wylie K, Mardis ER, Wilson RK, Fulton R, Kucaba TA, Wagner-McPherson C, Barbazuk WB, Gregory SG, Humphray SJ, French L, Evans RS, Bethel G, Whittaker A, Holden JL, McCann OT, Dunham A, Soderlund C, Scott CE, Bentley DR, Schuler G, Chen HC, Jang W, Green ED, Idol JR, Maduro VV, Montgomery KT, Lee E, Miller A, Emerling S, Kucherlapati, Gibbs R, Scherer S, Gorrell JH, Sodergren E, Clerc-Blankenburg K, Tabor P, Naylor S, Garcia D, de Jong PJ, Catanese JJ, Nowak N, Osoegawa K, Qin S, Rowen L, Madan A, Dors M, Hood L, Trask B, Friedman C, Massa H, Cheung VG, Kirsch IR, Reid T, Yonescu R, Weissenbach J, Bruls T, Heilig R, Branscomb E, Olsen A, Doggett N, Cheng JF, Hawkins T, Myers RM, Shang J, Ramirez L, Schmutz J, Velasquez O, Dixon K, Stone NE, Cox DR, Haussler D, Kent WJ, Furey T, Rogic S, Kennedy S, Jones S, Rosenthal A, Wen G, Schilhabel M, Gloeckner G, Nyakatura G, Siebert R, Schlegelberger B, Korenberg J, Chen XN, Fujiyama A, Hattori M, Toyoda A, Yada T, Park HS, Sakaki Y, Shimizu N, Asakawa S, et al (2001) A physical map of the human genome. Nature 409:934–941CrossRefPubMedGoogle Scholar
  13. Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki H, Sugiyama H, Noguchi S (2002) High expression of Wilms’ tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 8:1167–1171PubMedGoogle Scholar
  14. Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8:S55–61CrossRefPubMedGoogle Scholar
  15. Ono K, Tanaka T, Tsunoda T, Kitahara O, Kihara C, Okamoto A, Ochiai K, Takagi T, Nakamura Y (2000) Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60:5007–5011PubMedGoogle Scholar
  16. Powell BL, Bydder S, Grieu F, Gnanasampanthan G, Elsaleh H, Seshadri R, Berns EM, Iacopetta B (2001) Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients. Breast Cancer Res Treat 69:65–68CrossRefPubMedGoogle Scholar
  17. Ross CD, Gomaa MA, Gillies E, Juengel R, Medina JE (2000) Tumor grade, microvessel density, and activities of malate dehydrogenase, lactate dehydrogenase, and hexokinase in squamous cell carcinoma. Otolaryngol Head Neck Surg 122:195–200PubMedGoogle Scholar
  18. Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, Ferno M, Parwaresch R, Alm P (1999) Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 187:207–216CrossRefPubMedGoogle Scholar
  19. Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ (1996) Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer 69:135–141CrossRefPubMedGoogle Scholar
  20. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009CrossRefPubMedGoogle Scholar
  21. van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536CrossRefPubMedGoogle Scholar
  22. Xie D, Jauch A, Miller CW, Bartram CR, Koeffler HP (2002) Discovery of over-expressed genes and genetic alterations in breast cancer cells using a combination of suppression subtractive hybridization, multiplex FISH and comparative genomic hybridization. Int J Oncol 21:499–507PubMedGoogle Scholar
  23. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP (2002) Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30:e15CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Masamitsu Onda
    • 1
  • Mitsuru Emi
    • 1
  • Hisaki Nagai
    • 1
  • Takemitsu Nagahata
    • 1
  • Kouji Tsumagari
    • 1
  • Takashi Fujimoto
    • 1
  • Futoshi Akiyama
    • 2
  • Goi Sakamoto
    • 2
  • Masujirou Makita
    • 2
  • Fujio Kasumi
    • 2
  • Yoshio Miki
    • 2
  • Toshihiro Tanaka
    • 3
    • 4
  • Tatsuhiko Tsunoda
    • 3
  • Yusuke Nakamura
    • 4
  1. 1.Department of Molecular Biology, Institute of GerontologyNippon Medical SchoolKawasakiJapan
  2. 2.The Cancer InstituteKami-IkebukuroTokyoJapan
  3. 3.SNP Research CenterRIKEN (Institute of Physical and Chemical Research)YokohamaJapan
  4. 4.Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical ScienceUniversity of TokyoTokyoJapan

Personalised recommendations